Crinetics Receives FDA Approval for PALSONIFY™ (paltusotine) to Treat Adults with Acromegaly
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 25 2025
0mins
Should l Buy CRNX?
Source: Newsfilter
FDA Approval of PALSONIFY: The FDA has approved PALSONIFY (paltusotine) as the first once-daily, oral treatment for adults with acromegaly who have not responded adequately to surgery or for whom surgery is not an option, based on positive results from two pivotal Phase 3 trials.
Impact on Patients and Company: This approval represents a significant advancement in acromegaly treatment, providing a more convenient option for patients and marking a milestone for Crinetics Pharmaceuticals as a leader in endocrine-focused therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRNX
Wall Street analysts forecast CRNX stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.270
Low
67.00
Averages
89.40
High
105.00
Current: 34.270
Low
67.00
Averages
89.40
High
105.00
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Crinetics Pharmaceuticals Director Sells Shares
- Share Sale Details: On March 12, 2026, Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares for approximately $180,761, reducing his direct ownership to 16,300 shares, indicating a strategic liquidity move rather than a lack of confidence in the company.
- Market Reaction Analysis: The sale represented 23.47% of Coelho's direct holdings and occurred amidst a 4% decline in share price, suggesting that this transaction was more about liquidity needs than signaling positive business outlook.
- Financial Performance Overview: Crinetics reported $7.7 million in revenue for 2025, largely driven by the successful launch of its lead drug Palsonify, which generated $5.4 million in its first quarter, highlighting the company's potential in early commercialization.
- R&D Spending and Market Expansion: Despite R&D expenditures exceeding $330 million, Crinetics is expanding internationally, recently submitting a marketing application for Palsonify in Brazil, which could further enhance growth prospects moving forward.
See More
Crinetics Pharmaceuticals Director Sells 5,000 Shares
- Sale Overview: Rogerio Vivaldi Coelho, a director at Crinetics Pharmaceuticals, sold 5,000 shares of common stock on March 12, 2026, for approximately $181,000, reducing his direct holdings to 16,300 shares valued at around $595,000 post-transaction.
- Transaction Context: This sale accounted for 23.47% of Coelho's direct ownership, marking his first public open-market sale, executed automatically under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating a non-discretionary liquidity management strategy.
- Market Reaction and Valuation: The shares were sold at a weighted average price of about $36.15, closely aligned with the market close of $36.51 on March 12, 2026, suggesting that the transaction did not significantly impact market pricing, reflecting stability in the stock.
- Company Growth Prospects: Crinetics Pharmaceuticals generated $7.7 million in revenue for 2025, primarily driven by the successful launch of its lead drug, Palsonify, and despite R&D expenses exceeding $330 million, the company’s international expansion and $1.4 billion in cash post-offering position it well for future growth.
See More
Crinetics Pharmaceuticals COO Resignation and Future Plans
- Executive Resignation: Crinetics Pharmaceuticals' Chief Development and Operating Officer Jeff Knight will resign effective April 10, 2026, with his responsibilities and team reassigned to other executives, potentially impacting operational efficiency and decision-making processes.
- Financial Planning: The company outlines a $600 million to $650 million operating expense plan for 2026, aimed at supporting the accelerated launch of PALSONIFY, reflecting its commitment to the market potential of new products.
- Market Environment: Amid disruptions in the Middle East, Wall Street's focus on oversold mid-cap healthcare stocks has increased, placing Crinetics under greater market pressure and investor scrutiny.
- Investor Engagement: Crinetics presented at the TD Cowen 46th Annual Health Care Conference, indicating its proactive approach in communicating future strategies and financial health to investors.
See More
Crinetics Pharmaceuticals Q4 2025 Earnings Call Highlights
- Successful Product Launch: Crinetics' first commercial product, PALSONIFY, was successfully launched, with CEO Struthers noting over 200 enrollment forms received in Q4, indicating strong market demand and positioning the drug as the preferred treatment for acromegaly, thereby solidifying the company's market position in endocrinology.
- Strong Financial Performance: In Q4 2025, Crinetics reported total net revenue of $6.2 million, with $5.4 million from PALSONIFY's U.S. commercial sales and $0.8 million from a licensing agreement with a Japanese partner, showcasing a solid start in its commercialization efforts.
- Ongoing R&D Investment: Although R&D expenses for 2025 were $85.1 million, down from $90.5 million in Q3, the company plans to increase operating expenses in 2026 to support new clinical trials and PALSONIFY's commercialization, reflecting confidence in future growth.
- Healthy Cash Flow Position: By the end of 2025, Crinetics had over $1 billion in cash and cash equivalents, and with the January 2026 public offering, total funds are expected to reach approximately $1.4 billion, ensuring sufficient capital to fund operations into 2030 and supporting long-term growth potential.
See More
Analyst Target Prices Indicate Potential for Pharmaceuticals ETF
- ETF Upside Potential: The iShares U.S. Pharmaceuticals ETF (IHE) has an implied analyst target price of $96.28 per unit, while trading at $86.15, indicating an 11.76% upside, reflecting market optimism about the ETF's future performance.
- MBX Stock Analysis: MBX BIOSCIENCES INC (MBX) trades at $35.83, with an analyst target price of $60.55, suggesting a potential upside of 69.01%, showcasing investor confidence in its future prospects.
- CRNX Stock Outlook: Crinetics Pharmaceuticals Inc (CRNX) has a current price of $51.32 and an analyst target of $83.46, indicating a 62.63% upside, reflecting positive market sentiment regarding its product and R&D advancements.
- XERS Investment Opportunity: Xeris Biopharma Holdings Inc (XERS) is priced at $7.14, with an analyst target of $11.14, showing a 56.05% upside, indicating analysts' optimism about its growth potential.
See More
Crinetics Prices 7.62M Share Offering at $45.95, Raising $350M
- Offering Size: Crinetics Pharmaceuticals announced the pricing of 7.62 million shares at $45.95 each, expected to raise approximately $350 million, enhancing the company's financial capacity for future growth initiatives.
- Use of Proceeds: The proceeds will fund commercial activities related to PALSONIFY™, research and development of new product candidates, and other general corporate purposes, ensuring ongoing innovation in endocrine disease treatment.
- Underwriter Lineup: The offering is managed by Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler, and Cantor, reflecting strong market confidence and support for Crinetics.
- Market Outlook: With its lead product PALSONIFY™ approved by the FDA, Crinetics is positioned to drive growth in the endocrine tumor treatment market, further solidifying its industry standing.
See More
Crinetics Pharmaceuticals Director Sells Shares
- Share Sale Details: On March 12, 2026, Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares for approximately $180,761, reducing his direct ownership to 16,300 shares, indicating a strategic liquidity move rather than a lack of confidence in the company.
- Market Reaction Analysis: The sale represented 23.47% of Coelho's direct holdings and occurred amidst a 4% decline in share price, suggesting that this transaction was more about liquidity needs than signaling positive business outlook.
- Financial Performance Overview: Crinetics reported $7.7 million in revenue for 2025, largely driven by the successful launch of its lead drug Palsonify, which generated $5.4 million in its first quarter, highlighting the company's potential in early commercialization.
- R&D Spending and Market Expansion: Despite R&D expenditures exceeding $330 million, Crinetics is expanding internationally, recently submitting a marketing application for Palsonify in Brazil, which could further enhance growth prospects moving forward.
See More
Crinetics Pharmaceuticals Director Sells 5,000 Shares
- Sale Overview: Rogerio Vivaldi Coelho, a director at Crinetics Pharmaceuticals, sold 5,000 shares of common stock on March 12, 2026, for approximately $181,000, reducing his direct holdings to 16,300 shares valued at around $595,000 post-transaction.
- Transaction Context: This sale accounted for 23.47% of Coelho's direct ownership, marking his first public open-market sale, executed automatically under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating a non-discretionary liquidity management strategy.
- Market Reaction and Valuation: The shares were sold at a weighted average price of about $36.15, closely aligned with the market close of $36.51 on March 12, 2026, suggesting that the transaction did not significantly impact market pricing, reflecting stability in the stock.
- Company Growth Prospects: Crinetics Pharmaceuticals generated $7.7 million in revenue for 2025, primarily driven by the successful launch of its lead drug, Palsonify, and despite R&D expenses exceeding $330 million, the company’s international expansion and $1.4 billion in cash post-offering position it well for future growth.
See More
Crinetics Pharmaceuticals COO Resignation and Future Plans
- Executive Resignation: Crinetics Pharmaceuticals' Chief Development and Operating Officer Jeff Knight will resign effective April 10, 2026, with his responsibilities and team reassigned to other executives, potentially impacting operational efficiency and decision-making processes.
- Financial Planning: The company outlines a $600 million to $650 million operating expense plan for 2026, aimed at supporting the accelerated launch of PALSONIFY, reflecting its commitment to the market potential of new products.
- Market Environment: Amid disruptions in the Middle East, Wall Street's focus on oversold mid-cap healthcare stocks has increased, placing Crinetics under greater market pressure and investor scrutiny.
- Investor Engagement: Crinetics presented at the TD Cowen 46th Annual Health Care Conference, indicating its proactive approach in communicating future strategies and financial health to investors.
See More
Crinetics Pharmaceuticals Q4 2025 Earnings Call Highlights
- Successful Product Launch: Crinetics' first commercial product, PALSONIFY, was successfully launched, with CEO Struthers noting over 200 enrollment forms received in Q4, indicating strong market demand and positioning the drug as the preferred treatment for acromegaly, thereby solidifying the company's market position in endocrinology.
- Strong Financial Performance: In Q4 2025, Crinetics reported total net revenue of $6.2 million, with $5.4 million from PALSONIFY's U.S. commercial sales and $0.8 million from a licensing agreement with a Japanese partner, showcasing a solid start in its commercialization efforts.
- Ongoing R&D Investment: Although R&D expenses for 2025 were $85.1 million, down from $90.5 million in Q3, the company plans to increase operating expenses in 2026 to support new clinical trials and PALSONIFY's commercialization, reflecting confidence in future growth.
- Healthy Cash Flow Position: By the end of 2025, Crinetics had over $1 billion in cash and cash equivalents, and with the January 2026 public offering, total funds are expected to reach approximately $1.4 billion, ensuring sufficient capital to fund operations into 2030 and supporting long-term growth potential.
See More
Analyst Target Prices Indicate Potential for Pharmaceuticals ETF
- ETF Upside Potential: The iShares U.S. Pharmaceuticals ETF (IHE) has an implied analyst target price of $96.28 per unit, while trading at $86.15, indicating an 11.76% upside, reflecting market optimism about the ETF's future performance.
- MBX Stock Analysis: MBX BIOSCIENCES INC (MBX) trades at $35.83, with an analyst target price of $60.55, suggesting a potential upside of 69.01%, showcasing investor confidence in its future prospects.
- CRNX Stock Outlook: Crinetics Pharmaceuticals Inc (CRNX) has a current price of $51.32 and an analyst target of $83.46, indicating a 62.63% upside, reflecting positive market sentiment regarding its product and R&D advancements.
- XERS Investment Opportunity: Xeris Biopharma Holdings Inc (XERS) is priced at $7.14, with an analyst target of $11.14, showing a 56.05% upside, indicating analysts' optimism about its growth potential.
See More
Crinetics Prices 7.62M Share Offering at $45.95, Raising $350M
- Offering Size: Crinetics Pharmaceuticals announced the pricing of 7.62 million shares at $45.95 each, expected to raise approximately $350 million, enhancing the company's financial capacity for future growth initiatives.
- Use of Proceeds: The proceeds will fund commercial activities related to PALSONIFY™, research and development of new product candidates, and other general corporate purposes, ensuring ongoing innovation in endocrine disease treatment.
- Underwriter Lineup: The offering is managed by Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler, and Cantor, reflecting strong market confidence and support for Crinetics.
- Market Outlook: With its lead product PALSONIFY™ approved by the FDA, Crinetics is positioned to drive growth in the endocrine tumor treatment market, further solidifying its industry standing.
See More
